[go: up one dir, main page]

ECSP10010076A - Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso - Google Patents

Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso

Info

Publication number
ECSP10010076A
ECSP10010076A EC2010010076A ECSP10010076A ECSP10010076A EC SP10010076 A ECSP10010076 A EC SP10010076A EC 2010010076 A EC2010010076 A EC 2010010076A EC SP10010076 A ECSP10010076 A EC SP10010076A EC SP10010076 A ECSP10010076 A EC SP10010076A
Authority
EC
Ecuador
Prior art keywords
phenyl
amino
propanoate
trifluoroethoxy
pyrazole
Prior art date
Application number
EC2010010076A
Other languages
English (en)
Inventor
Paul Susan Margaret De
Haiming Zhang
Mark Stephen Bednarz
Ramanaiah C Kanamarlapudi
Anett Perlberg
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39944300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of ECSP10010076A publication Critical patent/ECSP10010076A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-il ) fenil) -2,2,2-trifluoroetoxi) pirimidin-4- il) fenil) propanoato y sus sales son descubiertas por esta aplicación de patente.
EC2010010076A 2007-09-28 2010-03-31 Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso ECSP10010076A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97584607P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
ECSP10010076A true ECSP10010076A (es) 2010-04-30

Family

ID=39944300

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010076A ECSP10010076A (es) 2007-09-28 2010-03-31 Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso

Country Status (25)

Country Link
US (2) US8193204B2 (es)
EP (1) EP2203444B1 (es)
JP (1) JP5717445B2 (es)
KR (1) KR101644657B1 (es)
CN (1) CN101809018B (es)
AR (1) AR068558A1 (es)
AU (1) AU2008304439B2 (es)
BR (1) BRPI0817270B1 (es)
CA (1) CA2700835C (es)
CL (1) CL2008002880A1 (es)
CO (1) CO6270325A2 (es)
DK (1) DK2203444T3 (es)
EA (1) EA017275B1 (es)
EC (1) ECSP10010076A (es)
ES (1) ES2431928T3 (es)
IL (1) IL204373A (es)
MX (1) MX2010003326A (es)
NZ (1) NZ583808A (es)
PE (1) PE20090742A1 (es)
PL (1) PL2203444T3 (es)
PT (1) PT2203444E (es)
TW (1) TWI439457B (es)
UA (1) UA102079C2 (es)
UY (1) UY31364A1 (es)
WO (1) WO2009042733A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265495B (zh) 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EA201070059A1 (ru) * 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Композиции, содержащие ингибиторы триптофангидроксилазы
EP2529740A1 (en) * 2007-08-24 2012-12-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
CA2719505A1 (en) * 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
WO2011056916A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
TW201302754A (zh) * 2010-11-05 2013-01-16 Lexicon Pharmaceuticals Inc ３－（４－（胺甲基）－１－（５－甲基－７ｈ－吡咯［２，３－ｄ］嘧啶－４－基）哌啶－４－甲醯胺基）苯基二甲基胺基甲酸酯之固態形式
DK2753306T3 (da) * 2011-10-17 2020-12-14 Lexicon Pharmaceuticals Inc Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
EP3061761A1 (en) 2015-02-24 2016-08-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3275885A1 (en) 2016-07-28 2018-01-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3363798A1 (en) 2017-02-20 2018-08-22 Esteve Química, S.A. Amorphous form of telotristat etiprate
CN109180650A (zh) * 2018-08-28 2019-01-11 湖南华腾制药有限公司 一种氘代色氨酸羟化酶抑制剂的晶型
WO2023192003A1 (en) 2022-04-01 2023-10-05 Tersera Therapeutics Llc Methods of reducing the likelihood of carcinoid heart disease in patients with neuroendocrine tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EP2529740A1 (en) * 2007-08-24 2012-12-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
TW200932729A (en) 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use

Also Published As

Publication number Publication date
EP2203444B1 (en) 2013-07-24
CL2008002880A1 (es) 2009-03-27
EA017275B1 (ru) 2012-11-30
BRPI0817270A2 (pt) 2017-06-06
HK1145023A1 (en) 2011-03-25
US20090088447A1 (en) 2009-04-02
AU2008304439B2 (en) 2013-10-17
CA2700835C (en) 2018-01-09
UY31364A1 (es) 2009-03-02
AU2008304439A1 (en) 2009-04-02
JP5717445B2 (ja) 2015-05-13
NZ583808A (en) 2012-01-12
US8193204B2 (en) 2012-06-05
UA102079C2 (en) 2013-06-10
CN101809018A (zh) 2010-08-18
KR20100063736A (ko) 2010-06-11
PE20090742A1 (es) 2009-07-08
BRPI0817270B1 (pt) 2022-02-08
CN101809018B (zh) 2013-02-06
TW200922934A (en) 2009-06-01
US20130005754A1 (en) 2013-01-03
MX2010003326A (es) 2010-04-09
TWI439457B (zh) 2014-06-01
PT2203444E (pt) 2013-09-12
PL2203444T3 (pl) 2013-12-31
DK2203444T3 (da) 2013-10-28
AR068558A1 (es) 2009-11-18
EA201070410A1 (ru) 2010-10-29
US8653094B2 (en) 2014-02-18
CA2700835A1 (en) 2009-04-02
ES2431928T3 (es) 2013-11-28
WO2009042733A1 (en) 2009-04-02
EP2203444A1 (en) 2010-07-07
IL204373A (en) 2013-12-31
JP2010540551A (ja) 2010-12-24
CO6270325A2 (es) 2011-04-20
KR101644657B1 (ko) 2016-08-01

Similar Documents

Publication Publication Date Title
ECSP10010076A (es) Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso
SV2007002813A (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
DK1945631T3 (da) 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
NO20081034L (no) Pyrimidinforbindelser som serotoninreseptormodulatorer
ECSP10010366A (es) Derivados de pirimidina 5-fluoro como fungicidas
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
DK1817300T3 (da) Forstærkere af glutamat-receptorer
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
DK2142516T3 (da) Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
NO20082517L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
UY31381A1 (es) Formas sólidas de ácido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3´-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico y sus métodos de uso
ATE407998T1 (de) Reinigungsmittel
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
BRPI0815754A2 (pt) métodos para preparar compostos à base de 4-fenil-6-(2,2,2-trifluoro-1-feniletóxi)pirimidina
SV2011003857A (es) Sales n-[6-(cis-2,6-dimetil-morfolin-4-il)- piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
EA201000069A1 (ru) Новые гербициды
ECSP11011167A (es) Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina
MX350019B (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida.
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
CY1108718T1 (el) Ενισχυται υποδοχεως αμρα